Innovent Biologics Inc

Incorporated in 2011, Innovent is a biopharmaceutical company with its headquarters located in Suzhou, Jiangsu Province, China. The company focuses on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, autoimmune, and metabolic diseases. Among its most important business segments are oncology, autoimmune, and metabolic diseases. Some of Innovent's key products include Tyvyt (sintilimab injection), an anti-PD-1 immunotherapy for cancer treatment; Byvasda (bevacizumab injection), an anti-VEGF monoclonal antibody; Halpryza (rituximab injection), an anti-CD20 monoclonal antibody; and Pemazyre (pemigatinib), which is used in the treatment of certain types of bile duct cancer (cholangiocarcinoma). While Innovent's products are mainly sold in China, the company is actively working on expanding its international reach. This expansion includes collaborations and licensing agreements aimed at accessing wider global markets. (Powered by AI)